{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:56:42Z","timestamp":1779163002836,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98701","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:57:27Z","timestamp":1765198647000},"source":"Crossref","is-referenced-by-count":1,"title":["Idiopathic Hyperprolactinemia: Clinical Presentation, Diagnosis, Management, and Clinical Outcome"],"prefix":"10.7759","author":[{"given":"Olabosipo","family":"Sholuade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goodness","family":"Njoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suma","family":"Kaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma A","family":"Fatteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kollukkad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96:273-88. 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch ME","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017, 317:516-24. 10.1001\/jama.2016.19699","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes V","year":"2011","unstructured":"dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011, 14:259-65. 10.1007\/s11102-010-0290-z","journal-title":"Pituitary"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpnec.2021.100049","article-title":"Plasma prolactin is higher in major depressive disorder and females, and associated with anxiety, hostility, somatization, psychotic symptoms and heart rate","volume":"6","author":"Elgellaie A","year":"2021","unstructured":"Elgellaie A, Larkin T, Kaelle J, Mills J, Thomas S. Plasma prolactin is higher in major depressive disorder and females, and associated with anxiety, hostility, somatization, psychotic symptoms and heart rate. Compr Psychoneuroendocrinol. 2021, 6:100049. 10.1016\/j.cpnec.2021.100049","journal-title":"Compr Psychoneuroendocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_30_22","article-title":"Management of psychiatric disorders in patients with endocrine disorders","volume":"64","author":"Mishra KK","year":"2022","unstructured":"Mishra KK, Sawant N, Garg S. Management of psychiatric disorders in patients with endocrine disorders. Indian J Psychiatry. 2022, 64:S402-13. 10.4103\/indianjpsychiatry.indianjpsychiatry_30_22","journal-title":"Indian J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2022.0075","article-title":"Hyperprolactinemia and insulin resistance","volume":"73","author":"Gierach M","year":"2022","unstructured":"Gierach M, Bruska-Sikorska M, Rojek M, Junik R. Hyperprolactinemia and insulin resistance. Endokrynol Pol. 2022, 73:959-67. 10.5603\/EP.a2022.0075","journal-title":"Endokrynol Pol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2023.101453","article-title":"Hyperprolactinemia due to prolactinoma has an adverse impact on bone health with predominant impact on trabecular bone: a systematic review and meta-analysis","volume":"27","author":"Nagendra L","year":"2024","unstructured":"Nagendra L, Dutta D, Mondal S, Kapoor N, Joshi A, Bhattacharya S. Hyperprolactinemia due to prolactinoma has an adverse impact on bone health with predominant impact on trabecular bone: a systematic review and meta-analysis. J Clin Densitom. 2024, 27:101453. 10.1016\/j.jocd.2023.101453","journal-title":"J Clin Densitom"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430174-idiopathic-hyperprolactinemia-clinical-presentation-diagnosis-management-and-clinical-outcome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:57:28Z","timestamp":1765198648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430174-idiopathic-hyperprolactinemia-clinical-presentation-diagnosis-management-and-clinical-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.98701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}